Comparison of the European and U.S. guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.

Benoît Delabays,Roxane de La Harpe,Peter Vollenweider,Stephane Fournier,Olivier Müller,Davide Strambo,Ian Graham,Frank L J Visseren,David Nanchen,Pedro Marques-Vidal,Julien Vaucher

European journal of preventive cardiology（2023）

引用 0|浏览26

暂无评分

摘要

Both 2022 USPSTF and 2021 ESC guidelines particularly reduced lipid-lowering therapy eligibility in women. Nearly half of women who faced an incident ASCVD were not eligible for lipid-lowering therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要